Safety & evidence

“GLOW”
side effects

GLOW is a seller name for one vial mixing GHK-Cu, BPC-157 and TB-500. What regulators, studies and adverse-event reports have recorded about the mix and its ingredients, and what nobody has measured. Dated 18 November 2026.

Short answerSafety & evidence · 7 min read · Updated 18 Nov 2026

GLOW’s side effects are unknown: we found no published study of the mix in any species (PubMed, 18 November 2026). GLOW is a seller name for one vial of GHK-Cu, BPC-157 and TB-500. FDA describes limited or no human safety data for each, its staff say injected BPC-157 and TB-500 “may pose a significant risk for immunogenicity”, and a mix makes reactions harder to trace.

Key takeaways

  • GLOW is a seller name for one vial mixing GHK-Cu, BPC-157 and TB-500. We found no published study or registered trial of the mix, so its side effects are unknown, not absent.
  • FDA describes limited human data for injectable GHK-Cu, too little clinical safety information to characterise BPC-157 and no human exposure data for TB-500; FDA staff wrote that injected BPC-157 and TB-500 “may pose a significant risk for immunogenicity”.
  • FDA staff judged one reaction to a BPC-157 and TB-500 product “likely due to the drug product”, but because it contained two peptides, could not assess whether BPC-157 played a role.
  • In November 2026 Australia’s TGA found no detectable TB-500 in three products from one brand, identified in a New South Wales police investigation, whose labels listed it.
  • HHS’s 2026 interim compounding policy applies only to products with a single active ingredient, because it is “easier to attribute adverse events” to one substance.

01“GLOW” side effects at a glance

What regulators, studies and reports have recorded, dated 18 November 2026.

QuestionWhat is recorded
What GLOW isA seller name for one vial mixing GHK-Cu, BPC-157 and TB-500. The amount of each is set by whoever fills the vial; no regulator or peer-reviewed source defines it.
Studies of the mixNone found in any species, and no registered trial (PubMed and ClinicalTrials.gov, 18 Nov 2026).
GHK-Cu, injectedFDA: “limited data in humans to inform safety-related considerations”; a possible risk of immune reactions from aggregation and impurities.
BPC-157FDA staff, 2026: “insufficient clinical safety information to characterize the safety profile”; given by injection or nasally, it “may pose a significant risk for immunogenicity”.
TB-500FDA has not identified human exposure data for products containing it; FDA staff, 2026: potential safety risks in humans “are unknown”; given by injection, it “may pose a significant risk for immunogenicity”.
A two-peptide productFDA staff judged one reaction to a BPC-157 and TB-500 product likely due to the product, but could not assess BPC-157’s role because it contained two peptides.
Regulator laboratory findingTGA, Nov 2026: “No TB-500 detected” in three products from one brand, identified in a New South Wales police investigation, whose labels listed TB-500 with other peptides.
Long-term safetyUnknown. We found no long-term human study of the mix or of any of its three peptides.

What GLOW is, and what each ingredient has been studied in: what is the “GLOW peptide”?

02What have regulators said about GLOW’s ingredients?

The regulator documents we read do not name GLOW. They speak about each ingredient, and about mixed products.

FDA, ingredient by ingredient. FDA’s compounding page (content current 22 April 2026) says compounded injectable GHK-Cu “may pose risk for immunogenicity due to the potential for aggregation and peptide-related impurities” and that “there are limited data in humans to inform safety-related considerations”. Immunogenicity is the tendency to provoke an immune response. For BPC-157, compounded drugs “may pose risk for immunogenicity for certain routes of administration”, and the agency “lacks sufficient information to know whether the drug would cause harm when administered to humans”. For TB-500, listed as “Thymosin beta-4, fragment (LKKTETQ), also known as TB-500”, FDA “has not identified any human exposure data” and “lacks important information regarding any safety issues raised by this drug”.

FDA staff, July 2026. Briefing an advisory committee, FDA staff found “insufficient clinical safety information to characterize the safety profile” of BPC-157. Of TB-500 they wrote that “potential safety risks associated with the use of TB-500 in humans are unknown”. Given by injection, and for BPC-157 also nasally, each “may pose a significant risk for immunogenicity, potentially amplified by aggregation as well as potential peptide-related impurities”, they wrote.

Australia. The TGA’s advisory of 5 November 2026 says: “Peptide products taken alone or in combination with other medicines can cause serious side effects.”

Mixed products. HHS’s interim policy of October 2026 on compounding six peptides, which is not an approval, applies only when the product “contains only a single Active Pharmaceutical Ingredient (API) listed in Appendix A”. HHS gives the reason: “It will be easier to attribute adverse events or clinical outcomes to a specific substance.” BPC-157 and TB-500 are on that list; GHK-Cu is not. Background: the HHS peptide policy.

03What have human studies recorded?

Nothing for the mix. For each ingredient on its own, the record is thin, and both halves of it matter.

  • GHK-Cu. The human studies we found applied it to the skin. Its cosmetic studies were small and short; the one PubMed-indexed randomised trial of a skin-care regimen had 13 completers. We found no controlled trial of GHK-Cu given any other way. Skin studies say nothing about an injected vial. Details: GHK-Cu side effects.
  • BPC-157. FDA staff reviewed five small, short human studies. No serious adverse events “appear to have been reported”, but the studies “were of short duration, had small sample sizes”, and the authors “provided limited information on safety data”. Details: BPC-157 side effects.
  • TB-500. FDA staff found no clinical study and no human exposure data for TB-500 by any route. A placebo-controlled phase 1/2 trial, NCT07487363, is recruiting. Details: TB-500.

Small, short studies can show that common, immediate problems were not obvious. They cannot show that uncommon or delayed ones do not happen, and none of them gave the three peptides together. Why that gap matters: are peptides safe?

04What adverse-event reports involve blends like GLOW?

A three-peptide product. FDA’s public adverse-event data (FAERS, since renamed the FDA Adverse Event Monitoring System; data to 28 October 2026) hold one report that lists a product labelled as a blend of GHK-Cu, BPC-157 and TB-500, among other products the person used (our search, 18 November 2026). The reporter named other products as the suspects: chorionic gonadotrophin and Ozempic (semaglutide), both prescription medicines, in a 2026 consumer report coded as “adverse drug reaction”, “malignant lymphoid neoplasm” and “product dispensed by unauthorised provider”. The report does not record how the blend was used. FDA says a report gives “no certainty that the reported adverse event was due to the suspect product”, and it does not receive every report.

Two-peptide products. FDA’s 2026 review of BPC-157 describes a woman who used a product labelled for research purposes that contained BPC-157 and TB-500 and developed darkening of the skin and gums, which returned when she used it again. FDA staff judged the reactions “likely due to the drug product”, but “because the product contained two peptides it is not possible to assess a potential relationship between BPC-157 and the reported AEs.” FDA’s TB-500 review found two complaint reports about “blended TB-500 and BPC-157”, without safety assessments. In FDA’s public adverse-event data, to 28 October 2026, our search also found three reports in which the reporter named a BPC-157 product and a thymosin product (listed as “thymosin” or “thymosin beta-4”) as suspects. One, from 2021, is coded “injection site swelling”, “injection site erythema” and “product sterility lacking”. Two, from 2026, also name other suspect products: one is coded “malaise”, “blood insulin decreased”, “product dispensing error”, “product label issue”, “wrong product administered” and “manufacturing production issue”; the other “histamine abnormal” and “product quality issue”. All three are coded as serious. None records whether the thymosin product was TB-500, and a report does not show what caused an event.

Why a mix makes reports harder to read. When one vial holds three peptides, a report alone cannot trace a reaction to one of them, and the vial may not hold what its label lists (next section). That is the reason HHS gives for its single-ingredient condition. None of these reports gives a rate or shows a cause.

Had a reaction to any product? Seek medical care first, then report it: how to report a reaction in the US, UK or Australia.

05Does a GLOW vial hold what its label says?

A regulator’s laboratory finding. In an advisory of 5 November 2026, the TGA published laboratory results for products from one brand, identified in a New South Wales police investigation. For three of them, all labelled as containing TB-500 alongside other peptides, the finding was “No TB-500 detected”: a BPC-157 and TB-500 product, and two blends labelled with GHK-Cu, BPC-157, TB-500, KPV and other ingredients. The TGA concluded that consumers cannot rely on these labels to know what substance, or what amount, a product contains. That advisory covers that brand only.

Why a blend is harder to check. A lab report for one peptide confirms one identity and one amount. A three-peptide vial needs three of each, matched to the batch number. A single purity figure for the whole vial cannot show that each peptide is present, or how much. How to read one: how to read a COA.

What else can go wrong. FDA’s compounding page names aggregation and peptide-related impurities as possible causes of immune reactions for injectable GHK-Cu and for TB-500. Whether three peptides stay intact together in one vial, or change one another, has not been studied in anything we found. Other documented cases: contamination and mislabeling. The general case for mixed vials: peptide blends.

06What we don’t know about GLOW side effects

  • What the mix does in people, animals or cells. We found no study of it.
  • Whether its three peptides interact, or stay intact together in one vial.
  • How often any reaction occurs. No study gives a rate, and adverse-event reports cannot.
  • Long-term effects of any of the three, given by injection.
  • What a given vial contains. A lab report shows only what the tested sample from that lot held, and only for the peptides it identifies and measures.

Suspected reaction to any product? Seek medical care first, then report it. For anything about your health, a doctor who knows you is the right call.

This is a plain-English summary of public documents and studies, checked on 18 Nov 2026. It is not medical advice.

RefSources

  1. U.S. Food and Drug Administration. Certain bulk drug substances for use in compounding that may present significant safety risks. Web page, content current as of 22 Apr 2026; read 18 Nov 2026. www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-s…
  2. U.S. Food and Drug Administration. FDA briefing document, Pharmacy Compounding Advisory Committee meeting of 23–24 July 2026: BPC-157-related bulk drug substances. Advisory committee briefing, 2026 (pp. 41–46); read 18 Nov 2026. www.fda.gov/media/193343/download
  3. U.S. Food and Drug Administration. FDA briefing document, Pharmacy Compounding Advisory Committee meeting of 23–24 July 2026: TB-500-related bulk drug substances. Advisory committee briefing, 2026 (pp. 30–31); read 18 Nov 2026. www.fda.gov/media/193349/download
  4. U.S. Food and Drug Administration. openFDA drug adverse event API (FAERS public data, last updated 28 Oct 2026): products named TB-500 or TB500 (1 report, 26810736, listing the product as concomitant), GHK* or “copper tripeptide” (3) and GLOW* (31, one a peptide product); BPC-157 names with “thymosin” named as a co-suspect (3: 19422121, 26495698, 27136848). Database queries, run 18 Nov 2026 and re-run by QA the same day; counts are ours. api.fda.gov/drug/event.json?search=patient.drug.medicinalpro…
  5. Therapeutic Goods Administration. TGA testing finds unapproved peptides do not contain what their labels claim. Safety advisory, 5 Nov 2026; read on the Internet Archive capture of 15 Nov 2026, the newest. www.tga.gov.au/safety/safety-monitoring-and-information/safe…
  6. U.S. Department of Health and Human Services. Enforcement discretion policy regarding 503A compounding using certain peptide bulk drug substances, with Appendices A and B. Policy document, Oct 2026; read on the Internet Archive capture of 15 Nov 2026 (hhs.gov returns 403 to automated fetch). www.hhs.gov/sites/default/files/hhs-503a-peptide-enforcement…
  7. PubMed searches (title and abstract): GHK-Cu names AND BPC-157 names, 8 results; GHK-Cu names AND TB-500 or thymosin beta names, 7; all three, 7. Every result is a review, commentary or letter. Database searches, 18 Nov 2026. pubmed.ncbi.nlm.nih.gov/?term=%28GHK%5Btiab%5D+OR+%22copper+…
  8. ClinicalTrials.gov. Searches for BPC-157, TB-500, GHK-Cu and copper tripeptide-1: no record tests two or more together; NCT07487363 (TB-500, phase 1/2, placebo-controlled, recruiting). Registry searches via API v2, 18 Nov 2026. clinicaltrials.gov/study/NCT07487363
  9. Miller TR, Wagner JD, Baack BR, Eisbach KJ. Effects of topical copper tripeptide complex on CO2 laser-resurfaced skin. Arch Facial Plast Surg, 2006;8(4):252–259. PMID 16847171. pubmed.ncbi.nlm.nih.gov/16847171/

Plain-English summary of public sources, not legal or medical advice. Last checked 18 Nov 2026.

Questions

What are the side effects of GLOW?

They are unknown, because no published study has tested the mix. For its ingredients, FDA describes limited human data for injectable GHK-Cu, too little clinical safety information to characterise BPC-157 and no human exposure data for TB-500, and its staff wrote that injected BPC-157 and TB-500 “may pose a significant risk for immunogenicity”.

Has GLOW been tested for safety?

Not as a mix. We found no published study in any species and no registered trial of GLOW (PubMed and ClinicalTrials.gov, 18 Nov 2026). Safety information exists only for some of its ingredients on their own, and it is thin.

Can a reaction to a mixed vial be traced to one peptide?

Often not. In one FDA case involving a BPC-157 and TB-500 product, FDA staff judged the reaction likely due to the product but could not assess BPC-157’s role because it contained two peptides. HHS limits its 2026 compounding policy to single-ingredient products for this reason.

Does a GLOW vial always contain what its label says?

A label alone cannot show that. In November 2026 the TGA found no TB-500 in three products from one brand, identified in a New South Wales police investigation, whose labels listed it. A lab report shows what the tested sample from a lot held, and only for the peptides it identifies and measures.

How do I report a reaction to a peptide blend?

Seek medical care first. Then report it to FDA MedWatch in the US, the MHRA Yellow Card scheme in the UK or the TGA in Australia; our reporting page explains each route.

Evidence before hype.

One email a week: new research explained and regulatory changes. No prices, no hype.

Get the 6:00 brief

Free. Unsubscribe any time.

Written by 6AM Research. Drafted from primary sources; every claim links to its source, and the page is dated. Editorial policy · How we check every page